More on Chiron, interesting they say their adjuvant has the capability to enhance immune response, and can cross-protect against other strains.....Is this because it's enhancing the immunce response.
Chiron also is studying the use of adjuvants with vaccines, which the HHS heavily supports. Results released Friday from a study sponsored by the National Institute of Allergy and Infectious Diseases of Chiron's H9N2 avian influenza vaccine candidate showed promising results. Like H5N1, H9N2 is a potential pandemic influenza strain that has caused serious illness in three people in Hong Kong in recent years
Data from the 96-patient study showed that Chiron's adjuvant MF59 significantly enhanced immune response. The lowest dose tested contained 3.75 micrograms of antigen per dose, only a quarter of the dose used in seasonal influenza vaccines. The company expects to soon conduct clinical studies of an adjuvanted H5N1 vaccine.
"What's really exciting about it is it shows that an adjuvant has great potential to make an avian flu vaccine more effective," Marquiss said, "first of all, because it would boost the immune response so you would need less vaccine per person and you could reach more people."
A second advantage, she said, is the adjuvant can provide a cross-protective effect, meaning the vaccine can protect against different strains.
Market Data 
Markets 
AI
